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Background: There is increasing evidence that, in addition to the well-known effects on 
musculoskeletal health, vitamin D status may be related to a number of non-skeletal diseases. 
An international expert panel formulated recommendations on vitamin D for clinical practice, 
taking into consideration the best evidence available based on published literature today. In 
addition, where data were limited to smaller clinical trials or epidemiologic studies, the panel 
made expert-opinion based recommendations. 
Methods: Twenty-five experts from various disciplines (classical clinical applications, 
cardiology, autoimmunity, and cancer) established draft recommendations during a 2-day 
meeting. Thereafter, representatives of all disciplines refined the recommendations and 
related texts, subsequently reviewed by all panelists. For all recommendations, panelists 
expressed the extent of agreement using a 5-point scale. 
Results and conclusion: Recommendations were restricted to clinical practice and concern 
adult patients with or at risk for fractures, falls, cardiovascular or autoimmune diseases, and 
cancer. The panel reached substantial agreement about the need for vitamin D 
supplementation in specific groups of patients in these clinical areas and the need for 
assessing their 25-hydroxyvitamin D (25(OH)D) serum levels for optimal clinical care.  
A target range of at least 30 to 40 ng/mL was recommended. As response to treatment varies 
by environmental factors and starting levels of 25(OH)D, testing may be warranted after at 
least 3 months of supplementation. An assay measuring both 25(OH)D2 and 25(OH)D3 is 
recommended. Dark-skinned or veiled individuals not exposed much to the sun, elderly and 
institutionalized individuals may be supplemented (800 IU/day) without baseline testing. 
 
 




Take home messages 
• The 25(OH)D level in specific groups of patients with or at risk for musculoskeletal 
health problems, cardiovascular disease, autoimmune disease and cancer should be 
above 30 ng/mL for optimal health benefit 
•  The expert panel agreed on an  upper safety limit for 25(OH)D of 100 ng/mL 
• In these patients, a large correcting dose can be proposed initially, followed by a 
maintenance treatment of 800 IU/day (or equivalent with intermittent dosing), which 
can be increased if levels remain insufficient during monitoring  
• Supplementation (800 IU/day) without baseline testing is recommended in dark-
skinned or veiled individuals not exposed much to the sun, elderly and 
institutionalized individuals 
• The interval between starting vitamin D supplementation and measuring/monitoring 
the 25(OH)D level should at least be 3 months 





1.1 Background and aim of the paper 
Once thought to have consequences only for bone health, vitamin D deficiency has been 
associated with a large number of conditions such as cancer, autoimmune disease, and 
cardiovascular disease. A large part of the population does not meet vitamin D requirements 
because vitamin D is mainly synthesized when the skin is exposed to ultraviolet (UV) B 
radiation and contemporary life is associated with reduced sun exposure (we expose less than 
5% of our skin to the sun) and use of UVB-blocking sunscreens [1]. Dark-skinned individuals 
require more sun exposure to have the same vitamin D production as people with less skin 
pigmentation, and the same is true for older versus younger individuals[2]. Dietary sources of 
vitamin D3 (cholecalciferol) are few and only significant in oily fish. Vitamin D2 
(ergocalciferol), the plant/mushroom form of vitamin D, is almost absent in the diet. 
Supplementation with vitamin D can be done either with vitamin D2 or vitamin D3 but 
availability of these two forms greatly differs between countries. The optimal serum level of 
25-hydroxyvitamin D (25(OH)D) -the primary circulating form of vitamin D- needed for 
optimal health is unknown. However, a recent benefit-risk assessment of vitamin D suggested 
that it may be similar or possibly higher than needed for optimal bone health and calcium 
metabolism[3]. 
 
The abundance of publications on vitamin D (PubMed search: 2,844 in 2000-2001 increasing 
to 4,635 in 2008-2009), differing in level of evidence and consequences for clinical practice, 
hinders the physician in assessing the importance of vitamin D status for a specific patient. 
Therefore, a 2-day Vitamin D Summit Meeting was held on 7-8 November 2009 in Paris, 
with the goal of translating current evidence from clinical, experimental and epidemiological 
studies into recommendations for everyday clinical practice. The recommendations are 
intended to be used in clinical practice and concern adult patients with, or individuals at risk 
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for, classical applications of vitamin D such as osteoporosis, chronic kidney disease (CKD), 
and endocrinopathies. On the other hand the recommendations apply to adult patients with, or 
individuals at least 18 years old at risk for, diseases in which the role of vitamin D is 
emerging such as cardiovascular and autoimmune diseases and cancer. Therefore, a 
multidisciplinary group of 25 experts, from 12 different countries, addressed the following 
questions with regard to the described population:  
• Who should be tested for vitamin D deficiency? 
•  What is the recommended range of serum 25(OH)D? 
• Who should be supplemented? 
• When should the testing be performed? 
This perspective differs from, and could result in another set of standards than policy 
documents intended for the community at large (e.g. Institute of Medicine[4] and Standing 
Committee of European Doctors[5]). Until the results of long-term large scale randomized 
controlled trials (RCTs) in the emerging fields are available, the recommendations presented 
in this paper should not be extrapolated to the general healthy population. 
1.2. Panel methodology 
The chairpersons of the meeting (MP, JCS, JJB, JL, YS, TW), all experts in the field, defined 
the format of the meeting and warranted that the participants consisted of experts on vitamin 
D in different clinical specialties. The meeting started with a plenary session in which the 
state of the art was outlined from different perspectives and disciplines. Afterwards, the most 
important literature referring to a disease area was discussed in group sessions per specialty 
and translated into recommendations for each specialty. The recommendations were then 




The paper, consisting of a brief summary of the most important evidence and 
recommendations for clinical practice, based on the literature review and the experience of the 
authors, was drafted by the chairpersons. The draft was reviewed by all panel members and a 
scoring system was applied to measure agreement for each of the recommendations. 
 
2. Classical and non-classical effects of vitamin D 
2.1  Classical clinical effects of vitamin D 
Vitamin D has an impact on bone density and bone quality. In addition, by increasing muscle 
strength, adequate vitamin D status reduces the risk of falling in older individuals. Therefore, 
vitamin D has a dual benefit for prevention of fractures in the elderly, a benefit on bone 
density and muscle strength. To determine the anti-fracture efficacy of oral vitamin D 
supplementation in individuals ≥ 65 years old, Bischoff-Ferrari et al. did a meta-analysis of 12 
double-blind RCTs for non-vertebral fractures (n = 42,279) and 8 RCTs for hip fractures (n = 
40,886)[6]. The pooled relative risk (RR) was 0.86 (95% CI, 0.77-0.96) for prevention of non-
vertebral fractures and 0.91 (95% CI, 0.78-1.05) for the prevention of hip fractures. However, 
there was a significant heterogeneity for both endpoints. Factors explaining the heterogeneity 
were ‘dose’ and ‘achieved blood 25(OH)D levels’. When looking at the trials with a high 
(482-770 IU/day or 12.0-19.25 µg/day) received dose (i.e. dose adjusted for adherence) of 
vitamin D, non-vertebral fractures were reduced by 20% and hip fractures by 18%, whereas 
doses < 400 IU/day did not show any effect and fracture reduction was only achieved in trial 
that achieved 25(OH)D levels of at least 30 to 40 ng/ml. 
 
Furthermore, vitamin D has been shown to improve muscle performance and reduce the risk 
of falling in community-dwelling as well as institutionalized elderly. A meta-analysis 
including 8 double-blind RCTs (n = 2,426) demonstrated that falling was significantly 
reduced by 13% in vitamin D supplemented individuals compared with those receiving 
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calcium or placebo[7]. Again, a significant heterogeneity by dose and achieved 25(OH)D 
levels was observed. Higher dose supplemental vitamin D (700-1000 IU/day) reduced the 
relative risk of falls by 19%. 
 
This translates to an achieved serum 25(OH)D level of at least 24 ng/mL (60 nmol/L, 
conversion factor 2.496) for anti-fall efficacy and at least 30 ng/mL for anti-fracture 
efficacy[8]. 
Further, both fall and fracture prevention continued to increase with higher achieved 
25(OH)D levels up to 44 ng/mL[3]. 
 
Another group of patients, in which the role of vitamin D in maintaining calcium homeostasis 
is very important, comprises those with CKD and/or on dialysis. Studies in these patients have 
shown that they commonly suffer from vitamin D deficiency[9-11]. Low 25(OH)D levels 
have been associated with atherosclerosis and endothelial dysfunction in patients with end 
stage renal disease and on hemodialysis[12] and increased 90-day mortality in patients on 
hemodialysis [11].  Furthermore, in patients with CKD 2-5, the 25(OH)D level is an 
independent predictor of disease progression and mortality[10;13]. Jean et al. prospectively 
showed that vitamin D supplementation decreased serum PTH without increasing 
phosphatemia or calcemia in dialysis patients[9]. 
 
2.2  Effects of vitamin D in non-classical clinical fields 
While the evidence on bone and muscle health is based on RCTs, the evidence on other 
disease areas is of a lower level. Trials are small to moderate sized and the outcomes of 
interest are often secondary outcomes. A meta-analysis of 18 RCTs including 57,311 
individuals concluded that vitamin D supplementation was associated with a decrease in total 
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mortality (RR 0.93; 95% CI, 0.77-0.96 compared to the control group)[14]. A large body of 
experimental and epidemiologic data is available, and summarized below. 
 
2.2.1 Effects of vitamin D on the cardiac system 
A low level of 25(OH)D appears to be an independent risk factor for cardiovascular events, 
although a causal relationship has yet to be supported by large interventional trials. The 
evidence on the link between vitamin D deficiency and myocardial diseases has recently been 
reviewed[15]. In addition to possible direct effects due to the presence of the vitamin D 
receptor (VDR) and of the 1-alpha hydroxylase enzyme in cardiomyocytes and other cells of 
the cardiovascular system[16], vitamin D has significant effects on several cardiovascular risk 
factors. Studies, ranging from animal trials to RCTs, have shown that vitamin D reduces 
inflammation[17], controls several matrix metalloproteinases (MMPs) involved in vascular 
calcification[18], improves endothelial function[19], controls the secretion of insulin and 
improves insulin sensitivity[20;21], and decreases parathyroid hormone (PTH) secretion[22]. 
Furthermore, as reviewed recently by Pilz et al.,[23] vitamin D status has been linked to 
arterial hypertension[24]. 
 
In a small RCT, 8 weeks of supplementation with vitamin D3 (800 UI/day) and calcium was 
more effective in reducing systolic blood pressure than calcium alone[25]. In the Women’s 
Health Initiative, an RCT including 36,282 postmenopausal women, vitamin D3 plus calcium 
supplementation did not reduce blood pressure, nor the risk of developing hypertension over 
seven years of follow-up; however in this trial supplementation consisted only of 400 IU/day 
and adherence to supplementation was only around 60%[26]. A recent meta-analysis of 8 
RCTs in patients with a mean baseline blood pressure above 140/90 mmHg concluded that 
vitamin D reduces blood pressure modestly but significantly in hypertensive patients[27]. 
Another RCT in 200 healthy overweight individuals in a weight-reduction program showed 
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that 12 months of vitamin D supplementation (83µg/day) resulted in a significant reduction of 
PTH, triglycerides and TNF-alpha compared to placebo, however the LDL-cholesterol 
concentration increased in the supplementation group[28]. 
 
Observational studies consistently indicate that 25(OH)D levels less than 15 ng/mL are 
associated with excess risk of cardiovascular events, when compared with levels >30-40 
ng/mL. A nested case-control study in 18,225 men in the Health Professionals Follow-up 
Study (men aged 40-75, free of diagnosed cardiovascular disease at blood collection) showed 
that men with a 25(OH)D level ≤ 15 ng/mL had an increased risk for myocardial infarction 
(MI) relatively to men with a 25(OH)D level ≥ 30 ng/mL (RR 2.42 ;95% CI, 1.35-3.84)[29]. 
Even men with a 25(OH)D level 22.6-29.9 ng/mL had an increased risk ( RR 1.60; 95% CI, 
1.10-2.32) compared with those with a 25(OH)D level ≥ 30 ng/mL. In the Framingham 
Offspring cohort study, the 25(OH)D level was measured in 1,739 participants without prior 
heart disease[30]. At a mean follow-up of 5.4 years, among those with hypertension, there 
was a two-fold increase in the risk of cardiovascular events for the participants with a 
25(OH)D level < 15 ng/mL compared to those with a 25(OH)D level ≥ 15 ng/mL. The 
LUdwigshafen RIsk and Cardiovascular health (LURIC) study, a prospective cohort 
comprising 3,300 patients referred to coronary angiography and followed for 7.7 years, 
demonstrated a strong association between vitamin D status and several cardiovascular 
outcomes, such as cardiovascular mortality[31], stroke[32], heart failure and sudden cardiac 
death with the lowest risk among those with the highest 25(OH)D level[33]. 
 
2.2.2  Vitamin D and the immune system 
Many autoimmune diseases such as type 1 diabetes mellitus or multiple sclerosis (MS) are 
more frequent in countries with less sunshine[34]. Studies using animal models of several 
autoimmune diseases have identified vitamin D as a potential modulator of differentiation, 
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proliferation and secretion processes in autoimmune reaction. Supplementation in humans 
may be preventive in a number of autoimmune disorders[35]. 
 
A Finnish birth-cohort study, including > 10,000 children born in 1966, showed that vitamin 
D supplementation during the first year of life (2,000 IU/day) was associated with a risk 
reduction of 78% for developing type 1 diabetes (followed-up until end 1997) compared to no 
supplementation or lower doses[36]. A few studies indicate that treatment with vitamin D 
could be beneficial as well in  reducing the risk of developing MS and diminishing 
exacerbations of MS in affected patients[37;38]. In addition, a small 28-week trial in which 
MS patients received 28,000 to 280,000 IU/week provided evidence that high-dose vitamin D 
supplementation is safe in these patients[39]. Although contradictory data exist concerning 
supplementation benefits in rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE), an association between low levels of 25(OH)D and SLE disease activity[40] or RA 
disease activity[41] has recently been shown. Furthermore, an inverse association between 
higher intake of vitamin D and risk of RA was demonstrated in the Iowa Women’s Health 
Study[42]. 
 
2.2.3 Vitamin D and oncology 
Many experimental data show that calcitriol stimulates apoptosis and differentiation and 
inhibits angiogenesis and proliferation in tumour cells[43].  Numerous association studies 
suggest that serum 25(OH)D levels are inversely associated with the risk of many types of 
cancer. Further, in some studies of patients with cancer, an association between low 25(OH)D 
levels and poor prognosis has been observed[44;45]. A meta-analysis of available studies 
indicated that there is a trend for lower incidence of colorectal carcinoma and adenoma with 
25(OH)D levels >20 ng/ml in dose-response association (International Agency for Research 
and Cancer (IARC) report 2008, conducted for WHO)[46]. For breast cancer, a pooled 
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analysis of 2 studies with 880 cases and 880 controls demonstrated that individuals with 
serum 25(OHD of approximately 52 ng/mL had 50% lower risk of breast cancer than those 
with levels <13 ng/mL[47]. In addition, a large case-control study on 1,394 post-menopausal 
breast cancer patients and 1,365 controls confirmed that the 25(OH)D level was significantly 
associated with lower breast cancer risk, particularly at levels above 20 ng/mL[48]. Based on 
the IARC report 2008, which included all the available observational studies on breast 
cancer, a decreased risk was associated with higher serum 25(OH) D in case-controls 
studies. However, results from prospective studies only are more heterogeneous and did not 
support a significant association between vitamin D status and breast cancer[46]. 
 
There have been no clinical trials with cancer incidence or mortality as a primary outcome to 
support causality between vitamin D status and cancer. However, one population based RCT 
found that calcium plus vitamin D supplementation decreased cancer incidence as a secondary 
outcome. In that study (n = 1179 healthy postmenopausal women aged >55 year), the level of 
25(OH)D at baseline was 29 ng/mL. Supplementation with 1100 IU/day increased serum 
25(OH)D to 38 ng/mL. After four years of treatment, the supplemented group had a 60% 
lower risk of developing cancer than the placebo group[49]. In another randomized trial, the 
Women’s Health Initiative, no effect of calcium and 400 IU vitamin D/day was found on the 
incidence of colorectal or breast cancer, which were secondary outcomes[50;51]. However, 
the dose of 400 IU used in that trial may have been inadequate to raise 25(OH)D blood levels 
significantly, particularly after factoring in adherence levels. 
 
3. Recommendations of the expert panel  
The authors acknowledged the lack of adequate RCT data in the non-musculoskeletal disease 
areas and the fact that most RCTs were performed in older individuals, but they formulated 
recommendations based on the available evidence, risk-benefit considerations and clinical 
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experience. All recommendations were individually scored using an agreement index ranging 
from 1 (not agree at all) to 5 (fully agree). The mean score is presented in the text next to each 
recommendation. 
 
3.1 Who should be tested for its serum 25(OH)D level? 
The authors distinguished between 2 groups of individuals seen in the clinic: 
a. those who should have a 25(OH)D test (summarized in Table 1) 
b. those who may be supplemented without a test at baseline because they are very likely 
to have low levels of 25(OH)D (further explained in 3.3) 
In addition to the individuals in whom testing is recommended (Table 1), testing could be 
considered in individuals at risk for hypertension or other cardiovascular diseases (agreement 
score 4.1).  
 
3.2 Recommended range of 25(OH)D 
Based upon the presented evidence,   a 25(OH)D level of 30-44 ng/mL provides optimal 
benefits for outcomes in musculoskeletal and cardiovascular health and cancer[3].  
Therefore, the panel recommended that the 25(OH)D level in individuals with or at risk for 
musculoskeletal health problems, cardiovascular disease, autoimmune disease and cancer, as 
indicated in Table 1, should be above 30 ng/mL (agreement score 4.8).  
It was emphasized that the measurement uncertainty related to the 25(OH)D assay must be 
taken into account (as for any biological parameter). According to recent reports, choosing a 
threshold of 30 ng/mL will ensure that the patient has a true concentration that is >20 
ng/mL[52;53]. The experts discussing the classical applications emphasized that this lower 
limit of 30 ng/mL is especially important for patients with secondary causes of osteoporosis 
such as primary hyperparathyroidism, as well as for patients with renal disease stage 3-5D 
(including thus dialysis patients), as stated in the most recent guidelines[54]. The effects of 
15 
 
seasonal variation should be taken into account and an attempt should be made to maintain 
the minimum level in all seasons. 
 
As vitamin D may be toxic at extremely high doses, the panel also considered the safety of the 
higher 25(OH)D levels and proposed an upper safety limit of 100 ng/mL (agreement score 4. 
6). Sunbathing can produce vitamin D doses equivalent to an oral vitamin D intake of up to 
20,000 IU per day and in healthy subjects who have spent prolonged periods in a sunny 
environment, measured 25(OH)D concentrations rarely exceed 100 ng/mL, suggesting that 
this level may be considered as a safe upper limit for serum 25(OH)D levels[55-57].  Most 
international authorities consider a vitamin D intake of 2,000 IU daily as absolutely safe, 
although a recent review found that even doses of up to 10,000 IU per day supplemented over 
several months did not lead to any adverse events[58].   
Furthermore,  a benefit-risk assessment of Vitamin D supplementation reports that 
hypercalcemia caused by excess vitamin D in generally healthy adults has been observed only 
if daily intake was > 100,000 IU or if the 25(OH)D level exceeded 100 ng/mL[3]. However, 
Bischoff-Ferrari pointed out that there are currently no data to support that levels above 50 
ng/mL would result in additional benefits than 30-44 ng/mL. Therefore, 100 ng/mL should be 
considered as a safety limit but not as an upper limit to target in clinical practice. At the 
Necker Hospital, to present an example from clinical practice, the range of vitamin D 
indicated on the lab report is 30-80 ng/mL, however, the dose of vitamin D supplementation 
is slightly reduced when measuring levels of 70-80 ng/mL. Although such levels are 
considered as absolutely safe, it is not the level targeted to obtain optimal health outcomes.  
The position of all individual participants regarding the range for serum 25(OH)D levels is 
indicated in Appendix 1, and a summary is presented in Table 2. 
 
3.3 Who should be supplemented, which supplements, and which doses should be used? 
16 
 
According to a rule of thumb, an intake of 1,000 IU vitamin D/day results in an increase of 
approximately 10 ng/mL in 25(OH)D, although individual responses are variable[59]. 
Supplementation without baseline 25(OH)D measurement is recommended for dark-skinned 
or veiled subjects not exposed much to the sun (agreement score: 4.5), individuals without 
musculoskeletal health problems, cardiovascular disease, autoimmune disease and cancer ≥ 
65 years old (agreement score: 4.2) and institutionalized subjects (agreement score: 4.4). In 
these individuals a dose of 800 IU/day (the standard dose of most RCTs) or its equivalent 
with an intermittent dosing regimen (i.e 100,000 IU every 3 months) is recommended 
(agreement score: 4.2). Although daily dosages seem more physiologic, several studies have 
reported that a dose of vitamin D3 given intermittently (i.e monthly), has approximately 
similar effects on 25(OH)D concentration as the same cumulative dose given daily for the 
same period[60].  Recently, an RCT showed that  administration of a single annual high dose 
(500,000 IU) of vitamin D  could result in adverse outcomes which were suggested to be 
related to the dosing regimen[61]. Therefore daily, weekly or monthly strategies may be 
preferred. 
 
Measurement of 25(OH)D and subsequent supplementation if <30 ng/mL is recommended for 
all other individuals listed in Table 1 (agreement score: 4.8). In these subjects, a large 
correcting dose can be proposed initially (e.g. 50,000 IU capsule of vitamin D2 once a week 
for 8 weeks as proposed in[1]), followed by a maintenance treatment. For this second phase, 
an initial dose of 800 IU/day is recommended (or its equivalent, with intermittent dosing), 
checking compliance and possibly increasing the dose if during monitoring the level remains 
insufficient (agreement score: 4.5). This is especially important for specific disease conditions 




The panel recognized that, due to important disparity among countries regarding the available 
forms and dosages of vitamin D, it is difficult to recommend a specific treatment regimen. 
According to what is available in a given country, the choice of a given supplementation 
regimen may depend on the preference of the patient. Observance of adherence to 
supplementation is essential. In countries where both vitamin D2 and vitamin D3 are available, 
supplementation with D3 is to be preferred, as it avoids problems with differences in 
25(OH)D assay specificity (agreement score: 4.7). It must be mentioned however that vitamin 
D2 and vitamin D3 seem to have similar effects on 25(OH)D levels when given as daily 
doses[62]. By contrast, supplementation using an intermittent regimen is much more reliable 
for vitamin D3 than it is for vitamin D2, as vitamin D3 maintains serum 25(OH)D 
concentration for a longer period[63;64]. The need for the addition of calcium to vitamin D is 
dependent on the patient’s diet. Strict vegetarians may prefer supplementation with vitamin 
D2 (plant origin) instead of D3 (animal origin). Similarly, for religious reasons, some patients 
may refuse to take a vitamin D supplement that is diluted in an alcoholic solution. 
 
3.4 When should the testing be performed and how often should the monitoring occur? 
As mentioned above, if supplementation is to be considered, baseline measurement should be 
performed with the exception of dark-skinned or veiled individuals not exposed much to the 
sun, individuals ≥ 65 years without musculoskeletal health problems, cardiovascular disease, 
autoimmune disease or cancer, and institutionalized subjects. Measurement (monitoring) of 
serum 25(OH)D is recommended after at least 3 months of supplementation with daily doses 
(to allow a plateau to be reached). In the case of an intermittent regimen, measurement of 
25(OH)D is recommended after at least 3 months, just prior to the administration of a dose 
(agreement score: 4.8). It is recommended that further monitoring be performed according to 
physician judgment, taking into account the dose of supplementation and changes in regimen 
or dose (agreement score: 4.1). In addition, monitoring 25(OH)D (as well as performing a 
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baseline test) can be very beneficial for compliance of the patient with supplementation. 
Monitoring of calcium levels is only required in patients with diseases such as primary 
hyperparathyroidism.  
 
Requirements concerning 25(OH)D assays are indicated in Table 3. The recommendation to 
use an assay that measures both 25(OH)D2 and 25(OH)D3 is very important in countries 
where vitamin D2 and vitamin D3 are both available for supplementation. In Denmark, as in 
several other countries, the D2 form (and not D3) is contained in all high dose vitamin D 
preparations available for prescription. In fact,   
a reference laboratory in Denmark recently reported that, an increasing number of the tested 
serum samples contained significant amounts of 25(OH)D2, with 3% containing a 
concentration >20 ng/mL[65]. 25(OH)D is very stable in serum. A recent article reported 
problems with gel tubes and subsequent measurement of 25(OH)D by LC-MS/MS[66]. So, 
until more data are available, we recommend avoiding gel tubes.  
 
4. Conclusions 
The role of vitamin D in maintaining normal calcium-phosphorus homeostasis is well-
established. Vitamin D deficiency leads to rickets in children and osteomalacia in adults, and 
long-term deficiency contributes to osteoporosis. More recently, vitamin D deficiency has 
been associated with other chronic conditions, including cardiovascular disease, autoimmune 
disease, and cancer. The current recommendations address vitamin D supplementation, testing 
and monitoring in individuals with or at risk for these diseases. Nonetheless, randomized trial 
data are needed to determine whether long-term supplementation with vitamin D has a 
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Table 1: Overview of individuals with or at risk for musculoskeletal health problems, 
cardiovascular disease, autoimmune disease and cancer in whom it is recommended to 











or at risk for 
osteoporosis  





with a recent fall 
accident 
 

























can lead to bone 
loss 




Obese individuals 4.3 20 Oncology   
Patients with 
diabetes 
















* Emphasis on premenopausal women with early breast cancer receiving adjuvant 
chemotherapy or gonadotropin-releasing hormone (GnRH) analogs, on breast cancer 
patients under anti-aromatase therapy and on prostate cancer patients under hormone 
ablative treatment is warranted because of the negative influence of the treatment on bone 
health  
** Number of authors that gave a score; the authors only expressed their agreement for the 




Table 2: Serum25(OH)D range (ng/mL) according to the authors 







Table 3: Requirements for 25(OH)D assays 
Requirements for 25(OH)D assays 
Choose an assay that measures both 25(OH)D2 and 25(OH)D3 
If using an assay that separates 25(OH)D2 and 25(OH)D3 (i.e. HPLC or LC/MS-MS) 
indicate the sum of the 2 compounds (25(OH)D2+25(OH)D3) as the main results in 
your results sheet 
Participate to an external quality control scheme that provides materials with a 
documented commutability with human sera (e.g. the UK based DEQAS) [67] 
An internal quality control program has to be carried out in every laboratory by using 
different levels samples and valuable criteria for rejecting or accepting “the analytical 
run" 
Do not use population-based reference values (i.e. the concentrations of an apparently 
healthy population) in addition to a recommended range for 25(OH)D. This is highly 
confusing for the clinician 
We recommend serum as the sample of choice. Try to avoid gel tubes until more data 
are available 




Appendix 1: Table on individual position of the 25 participants regarding the serum 
25(OH)D range  
Participants Proposed 25(OH)D range (ng/mL) 
Classical application group  
Heike A. Bischoff-Ferrari 30-100 
Jean-Jacques Body (co-chair) 30-100 
Etienne Cavalier 30-100 
Peter R. Ebeling 30-50 
Patrice Fardellone 30-100 
Lene Heickendorff 30-100 
Bruce W. Hollis 40-100 
Sofia Ish-Shalom 30-100 
Guillaume Jean 30-50 
Alvaro Largura 30-150 
Mario Plebani (general chair of the meeting) 30-100 
Jean-Claude Souberbielle (co-chair) 30-100 
Andre Valcour 30-100 
Oncology group  
Sara Gandini 30-100 
Joan M. Lappe (chair) 30-100 
Cardiology group  
Damien Gruson 30-100 
Alain P. Guérin 30-100 
Stefan Pilz 30-100 
Thomas J. Wang (chair) 30-100 
Armin Zittermann 30-80 
Autoimmunity group  
Philipp von Landenberg 30-100 
Tomas Olsson 30-100 
Charles Pierrot-Deseilligny 30-100 
Yehuda Shoenfeld (chair) 30-100 
Angela Tincani 30-100 
 
 
